AlloVir plans Phase 3 posoleucel enrollment completion in 2023; $234M cash

Kalaris Therapeutics, Inc.

Cash balance $234M as of Dec 31, 2022; FY 2023 operating expenses guided $150M-$170M.
Enrollment completion for all three posoleucel Phase 3 trials expected by end of 2023; data readouts in 2024.
Topline results from Phase 2 BKV treatment study in kidney transplant patients expected in Q1 2023.
Final Phase 2 multi-virus prevention data presented at ASH 2022 showed substantially lower infection rates.
CEO Diana Brainard to present at J.P. Morgan Healthcare Conference on Jan 10, 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).

Period: fiscal year 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash stock compensation expenses.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-004128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.